GlassScriptPhysician profile
Jeffrey A Loman
NPI 1063478394
$11,783.11
in general payments reported to CMS, 2019-2025
59 companies · $1,394 in 2025
The $1,394 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,385 · 2020: $1,595 · 2021: $2,001 · 2022: $1,679 · 2023: $1,487 · 2024: $1,242 · 2025: $1,394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,123.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,868.20 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,629.62 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $698.64 | 2019-2025 | Otezla, Repatha, Repatha |
| Glaxosmithkline, LLC. | $676.29 | 2019-2025 | Shingrix, Arexvy |
| Abbvie INC. | $539.78 | 2019-2025 | |
| Medtronic, INC. | $503.20 | 2021-2025 | Minimed 780g, Minimed 770g, Mycarelink |
| Lilly USA, LLC | $409.35 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $353.62 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $335.73 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $328.40 | 2019-2025 | Jardiance, Synjardy |
| Insulet Corporation | $292.40 | 2020-2025 | Omnipod |
| Allergan, INC. | $274.18 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $248.80 | 2019-2025 | |
| Corcept Therapeutics | $235.45 | 2021-2025 | Korlym |
| Pfizer INC. | $227.16 | 2019-2024 |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Loman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.